Skip to main content

Table 1 Osteoporotic fracture outcomes according to treatment group

From: The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial

Osteoporotic fractures

B-Vitamins

Placebo

Relative risk

p-value

(n = 4089)

(n = 4075)

(95% confidence interval)

(log-rank test)

N (%)

N (%)

  

Any

67 (1.6)

78 (1.1)

0.86 (0.62,1.18)

0.32

Hip

34 (0.8)

36 (0.9)

0.94 (0.59,1.50)

0.77

Wrist

7 (0.2)

8 (0.1)

0.87 (0.32,2.40)

0.78

Thoracic spine

4 (0.1)

5 (0.1)

0.80 (0.21,2.97)

0.70

Other

26 (0.6)

35 (0.9)

0.74 (0.45,1.23)

0.24

  1. Note: Only first fracture was used for each type of events. One patient could have multiple different types of fractures, so sum of fracture types could be more than the total of fractures.